Cellular and molecular events in colorectal cancer: biological mechanisms, cell death pathways, drug resistance and signalling network interactions

被引:9
作者
Yan, Lei [1 ]
Shi, Jia [2 ]
Zhu, Jiazuo [3 ]
机构
[1] Univ South China, Cent Hosp Shaoyang, Med Dept, Shaoyang, Peoples R China
[2] Univ South China, Cent Hosp Shaoyang, Dept Obstet & Gynecol, Shaoyang, Peoples R China
[3] Xuancheng City Cent Hosp, Dept Oncol, 117 Tong Rd, Xuancheng, Anhui, Peoples R China
基金
英国科研创新办公室;
关键词
Colorectal cancer; Gastrointestinal tumors; Genetic and epigenetic factors; Apoptosis; Autophagy; ESTROGEN-RECEPTOR-BETA; FACTOR-KAPPA-B; ISLAND METHYLATOR PHENOTYPE; DEFECTIVE MISMATCH REPAIR; ENDOTHELIAL GROWTH-FACTOR; COLON-CARCINOMA CELLS; MICROSATELLITE-INSTABILITY; BRAF MUTATION; CYCLOOXYGENASE-2; EXPRESSION; GENE-EXPRESSION;
D O I
10.1007/s12672-024-01163-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Colorectal cancer (CRC) is a leading cause of cancer-related deaths worldwide, affecting millions each year. It emerges from the colon or rectum, parts of the digestive system, and is closely linked to both genetic and environmental factors. In CRC, genetic mutations such as APC, KRAS, and TP53, along with epigenetic changes like DNA methylation and histone modifications, play crucial roles in tumor development and treatment responses. This paper delves into the complex biological underpinnings of CRC, highlighting the pivotal roles of genetic alterations, cell death pathways, and the intricate network of signaling interactions that contribute to the disease's progression. It explores the dysregulation of apoptosis, autophagy, and other cell death mechanisms, underscoring the aberrant activation of these pathways in CRC. Additionally, the paper examines how mutations in key molecular pathways, including Wnt, EGFR/MAPK, and PI3K, fuel CRC development, and how these alterations can serve as both diagnostic and prognostic markers. The dual function of autophagy in CRC, acting as a tumor suppressor or promoter depending on the context, is also scrutinized. Through a comprehensive analysis of cellular and molecular events, this research aims to deepen our understanding of CRC and pave the way for more effective diagnostics, prognostics, and therapeutic strategies. Colorectal cancer (CRC) is one of the leading causes of death among patients.CRC has been characterized with changes at the genetic and epigenetic factors.The molecular factors can be used as diagnostic and prognostic factors in CRC.The cell death mechanisms demonstrate dysregulation in CRC. Autophagy has aberrant activation in CRC and exerts dual function.
引用
收藏
页数:29
相关论文
共 315 条
[1]  
Abdullah Murdani, 2012, Gastroenterol Hepatol Bed Bench, V5, P71
[2]   Apoptotic pathways as a therapeutic target for colorectal cancer treatment [J].
Abraha, Aman M. ;
Ketema, Ezra B. .
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2016, 8 (08) :583-591
[3]   The role of cyclooxygenase 2 in ulcerative colitis-associated neoplasia [J].
Agoff, SN ;
Brentnall, TA ;
Crispin, DA ;
Taylor, SL ;
Raaka, S ;
Haggitt, RC ;
Reed, MW ;
Afonina, IA ;
Rabinovitch, PS ;
Stevens, AC ;
Feng, ZD ;
Bronner, MP .
AMERICAN JOURNAL OF PATHOLOGY, 2000, 157 (03) :737-745
[4]   Emerging trends in colorectal cancer: Dysregulated signaling pathways (Review) [J].
Ahmad, Rehan ;
Singh, Jaikee Kumar ;
Wunnava, Amoolya ;
Al-Obeed, Omar ;
Abdulla, Maha ;
Srivastava, Sandeep Kumar .
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2021, 47 (03)
[5]  
AIO, 2008, Health, welfare, cancer in Australia: an overview, 2008
[6]   Molecular pathways in colorectal cancer [J].
Al-Sohaily, Sam ;
Biankin, Andrew ;
Leong, Rupert ;
Kohonen-Corish, Maija ;
Warusavitarne, Janindra .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2012, 27 (09) :1423-1431
[7]   The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention [J].
Alao, John P. .
MOLECULAR CANCER, 2007, 6 (1)
[8]   Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08 [J].
Allegra, Carmen J. ;
Yothers, Greg ;
O'Connell, Michael J. ;
Sharif, Saima ;
Petrelli, Nicholas J. ;
Colangelo, Linda H. ;
Atkins, James N. ;
Seay, Thomas E. ;
Fehrenbacher, Louis ;
Goldberg, Richard M. ;
O'Reilly, Seamus ;
Chu, Luis ;
Azar, Catherine A. ;
Lopa, Samia ;
Wolmark, Norman .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (01) :11-16
[9]   Everolimus in colorectal cancer [J].
Altomare, Ivy ;
Hurwitz, Herbert .
EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (04) :505-513
[10]   A Phase II Trial of Bevacizumab plus Everolimus for Patients with Refractory Metastatic Colorectal Cancer [J].
Altomare, Ivy ;
Bendell, Johanna C. ;
Bullock, Karen E. ;
Uronis, Hope E. ;
Morse, Michael A. ;
Hsu, S. David ;
Zafar, S. Yousuf ;
Blobe, Gerard C. ;
Pang, Herbert ;
Honeycutt, Wanda ;
Sutton, Linda ;
Hurwitz, Herbert I. .
ONCOLOGIST, 2011, 16 (08) :1131-1137